nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—ABCB1—Tacrolimus—atopic dermatitis	0.102	0.231	CbGbCtD
Naltrexone—ABCB1—Loratadine—atopic dermatitis	0.0743	0.169	CbGbCtD
Naltrexone—ABCB1—Methylprednisolone—atopic dermatitis	0.068	0.155	CbGbCtD
Naltrexone—ABCB1—Betamethasone—atopic dermatitis	0.0442	0.1	CbGbCtD
Naltrexone—ABCB1—Prednisolone—atopic dermatitis	0.0436	0.0991	CbGbCtD
Naltrexone—ABCB1—Hydrocortisone—atopic dermatitis	0.0413	0.094	CbGbCtD
Naltrexone—ABCB1—Prednisone—atopic dermatitis	0.0412	0.0936	CbGbCtD
Naltrexone—ABCB1—Dexamethasone—atopic dermatitis	0.0257	0.0585	CbGbCtD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—CXCR3—atopic dermatitis	0.000369	0.00379	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—NPS—atopic dermatitis	0.000368	0.00378	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—TAC1—atopic dermatitis	0.000368	0.00378	CbGpPWpGaD
Naltrexone—OPRD1—G alpha (i) signalling events—CXCL10—atopic dermatitis	0.000367	0.00377	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR3—atopic dermatitis	0.000362	0.00372	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCR3—atopic dermatitis	0.000361	0.00371	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—IL5—atopic dermatitis	0.000358	0.00367	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—CCR3—atopic dermatitis	0.000357	0.00367	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CCL17—atopic dermatitis	0.000355	0.00364	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—CCL11—atopic dermatitis	0.000338	0.00347	CbGpPWpGaD
Naltrexone—OPRD1—Peptide ligand-binding receptors—CCR5—atopic dermatitis	0.000337	0.00346	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—CXCR3—atopic dermatitis	0.000336	0.00345	CbGpPWpGaD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—atopic dermatitis	0.000335	0.00344	CbGpPWpGaD
Naltrexone—OPRK1—Peptide ligand-binding receptors—CCL5—atopic dermatitis	0.000328	0.00337	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—NPS—atopic dermatitis	0.000323	0.00331	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—TAC1—atopic dermatitis	0.000323	0.00331	CbGpPWpGaD
Naltrexone—OPRM1—Peptide ligand-binding receptors—CXCL10—atopic dermatitis	0.000322	0.00331	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—CXCL10—atopic dermatitis	0.000322	0.0033	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCR3—atopic dermatitis	0.000316	0.00325	CbGpPWpGaD
Naltrexone—OPRD1—G alpha (i) signalling events—CCL5—atopic dermatitis	0.000316	0.00324	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—CCR3—atopic dermatitis	0.000314	0.00323	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—CXCR3—atopic dermatitis	0.000312	0.00321	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CCL22—atopic dermatitis	0.000307	0.00315	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR3—atopic dermatitis	0.000306	0.00314	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CCL27—atopic dermatitis	0.000301	0.0031	CbGpPWpGaD
Naltrexone—OPRK1—Peptide ligand-binding receptors—CCR5—atopic dermatitis	0.000296	0.00304	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL10—atopic dermatitis	0.000292	0.003	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CCL11—atopic dermatitis	0.000286	0.00293	CbGpPWpGaD
Naltrexone—OPRM1—TCR Signaling Pathway—CD4—atopic dermatitis	0.000285	0.00293	CbGpPWpGaD
Naltrexone—OPRD1—G alpha (i) signalling events—CCR5—atopic dermatitis	0.000285	0.00292	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—TAC1—atopic dermatitis	0.00028	0.00288	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—NPS—atopic dermatitis	0.00028	0.00288	CbGpPWpGaD
Naltrexone—OPRM1—Peptide ligand-binding receptors—CCL5—atopic dermatitis	0.000277	0.00285	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—CCL5—atopic dermatitis	0.000277	0.00284	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—CCR3—atopic dermatitis	0.000276	0.00283	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—CXCR3—atopic dermatitis	0.000275	0.00282	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CCL27—atopic dermatitis	0.000274	0.00281	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—TAC1—atopic dermatitis	0.000273	0.0028	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—NPS—atopic dermatitis	0.000273	0.0028	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—CXCL10—atopic dermatitis	0.000272	0.00279	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CCL22—atopic dermatitis	0.000269	0.00277	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR3—atopic dermatitis	0.000267	0.00275	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CCL27—atopic dermatitis	0.000264	0.00271	CbGpPWpGaD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—CCR5—atopic dermatitis	0.000264	0.00271	CbGpPWpGaD
Naltrexone—OPRM1—TCR Signaling Pathway—IL1B—atopic dermatitis	0.000264	0.00271	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—IL10—atopic dermatitis	0.000262	0.00269	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL10—atopic dermatitis	0.000256	0.00263	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—IL4—atopic dermatitis	0.000255	0.00261	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL5—atopic dermatitis	0.000251	0.00258	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—TRPV3—atopic dermatitis	0.00025	0.00257	CbGpPWpGaD
Naltrexone—OPRM1—Peptide ligand-binding receptors—CCR5—atopic dermatitis	0.00025	0.00257	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—CCR5—atopic dermatitis	0.000249	0.00256	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—TAC1—atopic dermatitis	0.000246	0.00252	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—NPS—atopic dermatitis	0.000246	0.00252	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CCL17—atopic dermatitis	0.000246	0.00252	CbGpPWpGaD
Naltrexone—OPRM1—TCR Signaling Pathway—MAPK8—atopic dermatitis	0.000242	0.00248	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—CXCR3—atopic dermatitis	0.000241	0.00247	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CCL27—atopic dermatitis	0.00024	0.00246	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—CCL5—atopic dermatitis	0.000234	0.0024	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CCR3—atopic dermatitis	0.000233	0.00239	CbGpPWpGaD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—CCR5—atopic dermatitis	0.000232	0.00238	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CCL22—atopic dermatitis	0.000228	0.00234	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR5—atopic dermatitis	0.000226	0.00232	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CCL27—atopic dermatitis	0.000223	0.00229	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—CXCL10—atopic dermatitis	0.000222	0.00228	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL5—atopic dermatitis	0.00022	0.00226	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL10—atopic dermatitis	0.000216	0.00222	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CCL17—atopic dermatitis	0.000215	0.00221	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—CCR5—atopic dermatitis	0.000211	0.00217	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—TAC1—atopic dermatitis	0.000208	0.00213	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—NPS—atopic dermatitis	0.000208	0.00213	CbGpPWpGaD
Naltrexone—OPRD1—Peptide ligand-binding receptors—CXCL8—atopic dermatitis	0.000204	0.00209	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CXCR3—atopic dermatitis	0.000204	0.00209	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CCL27—atopic dermatitis	0.000203	0.00208	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR5—atopic dermatitis	0.000198	0.00204	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CCL11—atopic dermatitis	0.000198	0.00203	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—CCR5—atopic dermatitis	0.000196	0.00201	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—FCER2—atopic dermatitis	0.000195	0.002	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—CXCL10—atopic dermatitis	0.000195	0.002	CbGpPWpGaD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—atopic dermatitis	0.000195	0.000421	CcSEcCtD
Naltrexone—Syncope—Triamcinolone—atopic dermatitis	0.000194	0.00042	CcSEcCtD
Naltrexone—Syncope—Methylprednisolone—atopic dermatitis	0.000194	0.000419	CcSEcCtD
Naltrexone—Discomfort—Hydrocortisone—atopic dermatitis	0.000194	0.000419	CcSEcCtD
Naltrexone—Connective tissue disorder—Prednisone—atopic dermatitis	0.000193	0.000418	CcSEcCtD
Naltrexone—Anaphylactic shock—Prednisolone—atopic dermatitis	0.000192	0.000416	CcSEcCtD
Naltrexone—Oedema—Prednisolone—atopic dermatitis	0.000192	0.000416	CcSEcCtD
Naltrexone—Vomiting—Tacrolimus—atopic dermatitis	0.000192	0.000414	CcSEcCtD
Naltrexone—OPRD1—GPCR ligand binding—CCL5—atopic dermatitis	0.000191	0.00196	CbGpPWpGaD
Naltrexone—Loss of consciousness—Triamcinolone—atopic dermatitis	0.000191	0.000412	CcSEcCtD
Naltrexone—Loss of consciousness—Methylprednisolone—atopic dermatitis	0.00019	0.000411	CcSEcCtD
Naltrexone—Rash—Tacrolimus—atopic dermatitis	0.00019	0.00041	CcSEcCtD
Naltrexone—Dermatitis—Tacrolimus—atopic dermatitis	0.00019	0.00041	CcSEcCtD
Naltrexone—Shock—Prednisolone—atopic dermatitis	0.000189	0.000409	CcSEcCtD
Naltrexone—Cough—Triamcinolone—atopic dermatitis	0.000189	0.000409	CcSEcCtD
Naltrexone—Headache—Tacrolimus—atopic dermatitis	0.000189	0.000408	CcSEcCtD
Naltrexone—Oedema—Hydrocortisone—atopic dermatitis	0.000188	0.000406	CcSEcCtD
Naltrexone—Anaphylactic shock—Hydrocortisone—atopic dermatitis	0.000188	0.000406	CcSEcCtD
Naltrexone—Convulsion—Triamcinolone—atopic dermatitis	0.000188	0.000406	CcSEcCtD
Naltrexone—Tachycardia—Prednisolone—atopic dermatitis	0.000188	0.000406	CcSEcCtD
Naltrexone—Convulsion—Methylprednisolone—atopic dermatitis	0.000187	0.000405	CcSEcCtD
Naltrexone—Hypertension—Triamcinolone—atopic dermatitis	0.000187	0.000405	CcSEcCtD
Naltrexone—Hypertension—Methylprednisolone—atopic dermatitis	0.000187	0.000404	CcSEcCtD
Naltrexone—Infection—Hydrocortisone—atopic dermatitis	0.000187	0.000403	CcSEcCtD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—atopic dermatitis	0.000186	0.00191	CbGpPWpGaD
Naltrexone—Hyperhidrosis—Prednisolone—atopic dermatitis	0.000186	0.000402	CcSEcCtD
Naltrexone—Shock—Hydrocortisone—atopic dermatitis	0.000185	0.0004	CcSEcCtD
Naltrexone—Myalgia—Triamcinolone—atopic dermatitis	0.000185	0.000399	CcSEcCtD
Naltrexone—Nervous system disorder—Hydrocortisone—atopic dermatitis	0.000184	0.000398	CcSEcCtD
Naltrexone—Arthralgia—Methylprednisolone—atopic dermatitis	0.000184	0.000398	CcSEcCtD
Naltrexone—Myalgia—Methylprednisolone—atopic dermatitis	0.000184	0.000398	CcSEcCtD
Naltrexone—Eye disorder—Prednisone—atopic dermatitis	0.000184	0.000397	CcSEcCtD
Naltrexone—Anxiety—Methylprednisolone—atopic dermatitis	0.000184	0.000397	CcSEcCtD
Naltrexone—Tachycardia—Hydrocortisone—atopic dermatitis	0.000183	0.000396	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—atopic dermatitis	0.000183	0.000395	CcSEcCtD
Naltrexone—Skin disorder—Hydrocortisone—atopic dermatitis	0.000183	0.000394	CcSEcCtD
Naltrexone—Ill-defined disorder—Dexamethasone—atopic dermatitis	0.000183	0.000394	CcSEcCtD
Naltrexone—Ill-defined disorder—Betamethasone—atopic dermatitis	0.000183	0.000394	CcSEcCtD
Naltrexone—Discomfort—Triamcinolone—atopic dermatitis	0.000182	0.000394	CcSEcCtD
Naltrexone—OPRM1—Signaling by GPCR—CCL17—atopic dermatitis	0.000182	0.00187	CbGpPWpGaD
Naltrexone—Discomfort—Methylprednisolone—atopic dermatitis	0.000182	0.000393	CcSEcCtD
Naltrexone—Hyperhidrosis—Hydrocortisone—atopic dermatitis	0.000182	0.000393	CcSEcCtD
Naltrexone—OPRD1—Signaling Pathways—CCL22—atopic dermatitis	0.000181	0.00186	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—CASP8—atopic dermatitis	0.000181	0.00186	CbGpPWpGaD
Naltrexone—Dry mouth—Triamcinolone—atopic dermatitis	0.000181	0.00039	CcSEcCtD
Naltrexone—Angioedema—Betamethasone—atopic dermatitis	0.00018	0.000388	CcSEcCtD
Naltrexone—Angioedema—Dexamethasone—atopic dermatitis	0.00018	0.000388	CcSEcCtD
Naltrexone—Anorexia—Hydrocortisone—atopic dermatitis	0.000179	0.000387	CcSEcCtD
Naltrexone—Nausea—Tacrolimus—atopic dermatitis	0.000179	0.000387	CcSEcCtD
Naltrexone—OPRK1—Peptide ligand-binding receptors—CXCL8—atopic dermatitis	0.000179	0.00184	CbGpPWpGaD
Naltrexone—Angiopathy—Prednisone—atopic dermatitis	0.000179	0.000386	CcSEcCtD
Naltrexone—Confusional state—Methylprednisolone—atopic dermatitis	0.000178	0.000385	CcSEcCtD
Naltrexone—Immune system disorder—Prednisone—atopic dermatitis	0.000178	0.000384	CcSEcCtD
Naltrexone—OPRD1—GPCR downstream signaling—CCR3—atopic dermatitis	0.000178	0.00182	CbGpPWpGaD
Naltrexone—Malaise—Betamethasone—atopic dermatitis	0.000177	0.000383	CcSEcCtD
Naltrexone—Malaise—Dexamethasone—atopic dermatitis	0.000177	0.000383	CcSEcCtD
Naltrexone—Anaphylactic shock—Triamcinolone—atopic dermatitis	0.000177	0.000382	CcSEcCtD
Naltrexone—Oedema—Triamcinolone—atopic dermatitis	0.000177	0.000382	CcSEcCtD
Naltrexone—Anaphylactic shock—Methylprednisolone—atopic dermatitis	0.000177	0.000382	CcSEcCtD
Naltrexone—Syncope—Dexamethasone—atopic dermatitis	0.000176	0.000381	CcSEcCtD
Naltrexone—Syncope—Betamethasone—atopic dermatitis	0.000176	0.000381	CcSEcCtD
Naltrexone—Infection—Triamcinolone—atopic dermatitis	0.000176	0.00038	CcSEcCtD
Naltrexone—Infection—Methylprednisolone—atopic dermatitis	0.000175	0.000379	CcSEcCtD
Naltrexone—Shock—Triamcinolone—atopic dermatitis	0.000174	0.000376	CcSEcCtD
Naltrexone—Insomnia—Prednisolone—atopic dermatitis	0.000174	0.000376	CcSEcCtD
Naltrexone—Alopecia—Prednisone—atopic dermatitis	0.000174	0.000376	CcSEcCtD
Naltrexone—Shock—Methylprednisolone—atopic dermatitis	0.000174	0.000375	CcSEcCtD
Naltrexone—OPRK1—Signaling by GPCR—CCL11—atopic dermatitis	0.000174	0.00178	CbGpPWpGaD
Naltrexone—Nervous system disorder—Methylprednisolone—atopic dermatitis	0.000173	0.000374	CcSEcCtD
Naltrexone—Loss of consciousness—Betamethasone—atopic dermatitis	0.000173	0.000374	CcSEcCtD
Naltrexone—Loss of consciousness—Dexamethasone—atopic dermatitis	0.000173	0.000374	CcSEcCtD
Naltrexone—Paraesthesia—Prednisolone—atopic dermatitis	0.000173	0.000373	CcSEcCtD
Naltrexone—Tachycardia—Triamcinolone—atopic dermatitis	0.000173	0.000373	CcSEcCtD
Naltrexone—Mental disorder—Prednisone—atopic dermatitis	0.000172	0.000373	CcSEcCtD
Naltrexone—Tachycardia—Methylprednisolone—atopic dermatitis	0.000172	0.000372	CcSEcCtD
Naltrexone—OPRD1—GPCR ligand binding—CCR5—atopic dermatitis	0.000172	0.00177	CbGpPWpGaD
Naltrexone—OPRD1—G alpha (i) signalling events—CXCL8—atopic dermatitis	0.000172	0.00177	CbGpPWpGaD
Naltrexone—Skin disorder—Methylprednisolone—atopic dermatitis	0.000171	0.000371	CcSEcCtD
Naltrexone—Malnutrition—Prednisone—atopic dermatitis	0.000171	0.00037	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Hydrocortisone—atopic dermatitis	0.000171	0.00037	CcSEcCtD
Naltrexone—OPRK1—Signaling Pathways—FCER2—atopic dermatitis	0.000171	0.00176	CbGpPWpGaD
Naltrexone—Hyperhidrosis—Triamcinolone—atopic dermatitis	0.000171	0.00037	CcSEcCtD
Naltrexone—Hyperhidrosis—Methylprednisolone—atopic dermatitis	0.000171	0.000369	CcSEcCtD
Naltrexone—Convulsion—Betamethasone—atopic dermatitis	0.00017	0.000368	CcSEcCtD
Naltrexone—Convulsion—Dexamethasone—atopic dermatitis	0.00017	0.000368	CcSEcCtD
Naltrexone—Insomnia—Hydrocortisone—atopic dermatitis	0.00017	0.000367	CcSEcCtD
Naltrexone—Hypertension—Dexamethasone—atopic dermatitis	0.00017	0.000367	CcSEcCtD
Naltrexone—Hypertension—Betamethasone—atopic dermatitis	0.00017	0.000367	CcSEcCtD
Naltrexone—Paraesthesia—Hydrocortisone—atopic dermatitis	0.000169	0.000365	CcSEcCtD
Naltrexone—OPRK1—GPCR ligand binding—CCL5—atopic dermatitis	0.000168	0.00172	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—atopic dermatitis	0.000168	0.00172	CbGpPWpGaD
Naltrexone—Myalgia—Betamethasone—atopic dermatitis	0.000167	0.000362	CcSEcCtD
Naltrexone—Myalgia—Dexamethasone—atopic dermatitis	0.000167	0.000362	CcSEcCtD
Naltrexone—Anxiety—Betamethasone—atopic dermatitis	0.000167	0.000361	CcSEcCtD
Naltrexone—Anxiety—Dexamethasone—atopic dermatitis	0.000167	0.000361	CcSEcCtD
Naltrexone—Discomfort—Betamethasone—atopic dermatitis	0.000165	0.000358	CcSEcCtD
Naltrexone—Discomfort—Dexamethasone—atopic dermatitis	0.000165	0.000358	CcSEcCtD
Naltrexone—OPRM1—GPCR ligand binding—CXCL10—atopic dermatitis	0.000165	0.00169	CbGpPWpGaD
Naltrexone—Pain—Prednisolone—atopic dermatitis	0.000165	0.000356	CcSEcCtD
Naltrexone—Decreased appetite—Hydrocortisone—atopic dermatitis	0.000163	0.000353	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Hydrocortisone—atopic dermatitis	0.000162	0.000351	CcSEcCtD
Naltrexone—Fatigue—Hydrocortisone—atopic dermatitis	0.000162	0.00035	CcSEcCtD
Naltrexone—OPRD1—Signaling Pathways—CCL27—atopic dermatitis	0.000162	0.00166	CbGpPWpGaD
Naltrexone—Vision blurred—Prednisone—atopic dermatitis	0.000161	0.000349	CcSEcCtD
Naltrexone—OPRD1—Signaling by GPCR—CCR3—atopic dermatitis	0.000161	0.00166	CbGpPWpGaD
Naltrexone—Musculoskeletal discomfort—Triamcinolone—atopic dermatitis	0.000161	0.000348	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Methylprednisolone—atopic dermatitis	0.000161	0.000348	CcSEcCtD
Naltrexone—Pain—Hydrocortisone—atopic dermatitis	0.000161	0.000347	CcSEcCtD
Naltrexone—Oedema—Dexamethasone—atopic dermatitis	0.000161	0.000347	CcSEcCtD
Naltrexone—Anaphylactic shock—Dexamethasone—atopic dermatitis	0.000161	0.000347	CcSEcCtD
Naltrexone—Anaphylactic shock—Betamethasone—atopic dermatitis	0.000161	0.000347	CcSEcCtD
Naltrexone—Oedema—Betamethasone—atopic dermatitis	0.000161	0.000347	CcSEcCtD
Naltrexone—Insomnia—Triamcinolone—atopic dermatitis	0.00016	0.000346	CcSEcCtD
Naltrexone—Insomnia—Methylprednisolone—atopic dermatitis	0.00016	0.000345	CcSEcCtD
Naltrexone—Infection—Betamethasone—atopic dermatitis	0.000159	0.000345	CcSEcCtD
Naltrexone—Infection—Dexamethasone—atopic dermatitis	0.000159	0.000345	CcSEcCtD
Naltrexone—OPRK1—Signaling Pathways—CCL22—atopic dermatitis	0.000159	0.00163	CbGpPWpGaD
Naltrexone—Ill-defined disorder—Prednisone—atopic dermatitis	0.000159	0.000344	CcSEcCtD
Naltrexone—Paraesthesia—Triamcinolone—atopic dermatitis	0.000159	0.000343	CcSEcCtD
Naltrexone—Feeling abnormal—Prednisolone—atopic dermatitis	0.000159	0.000343	CcSEcCtD
Naltrexone—Paraesthesia—Methylprednisolone—atopic dermatitis	0.000159	0.000343	CcSEcCtD
Naltrexone—OPRD1—GPCR downstream signaling—TAC1—atopic dermatitis	0.000158	0.00163	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—NPS—atopic dermatitis	0.000158	0.00163	CbGpPWpGaD
Naltrexone—Shock—Betamethasone—atopic dermatitis	0.000158	0.000341	CcSEcCtD
Naltrexone—Shock—Dexamethasone—atopic dermatitis	0.000158	0.000341	CcSEcCtD
Naltrexone—Dyspnoea—Triamcinolone—atopic dermatitis	0.000158	0.000341	CcSEcCtD
Naltrexone—Nervous system disorder—Betamethasone—atopic dermatitis	0.000157	0.00034	CcSEcCtD
Naltrexone—Nervous system disorder—Dexamethasone—atopic dermatitis	0.000157	0.00034	CcSEcCtD
Naltrexone—Agitation—Prednisone—atopic dermatitis	0.000157	0.00034	CcSEcCtD
Naltrexone—Tachycardia—Dexamethasone—atopic dermatitis	0.000157	0.000339	CcSEcCtD
Naltrexone—Tachycardia—Betamethasone—atopic dermatitis	0.000157	0.000339	CcSEcCtD
Naltrexone—Angioedema—Prednisone—atopic dermatitis	0.000157	0.000338	CcSEcCtD
Naltrexone—OPRK1—GPCR downstream signaling—CCR3—atopic dermatitis	0.000156	0.0016	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CXCR3—atopic dermatitis	0.000155	0.00159	CbGpPWpGaD
Naltrexone—Hyperhidrosis—Dexamethasone—atopic dermatitis	0.000155	0.000335	CcSEcCtD
Naltrexone—Hyperhidrosis—Betamethasone—atopic dermatitis	0.000155	0.000335	CcSEcCtD
Naltrexone—Feeling abnormal—Hydrocortisone—atopic dermatitis	0.000155	0.000335	CcSEcCtD
Naltrexone—Malaise—Prednisone—atopic dermatitis	0.000154	0.000334	CcSEcCtD
Naltrexone—OPRM1—TCR Signaling Pathway—IL6—atopic dermatitis	0.000154	0.00158	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—IFNG—atopic dermatitis	0.000154	0.00158	CbGpPWpGaD
Naltrexone—Gastrointestinal pain—Hydrocortisone—atopic dermatitis	0.000154	0.000332	CcSEcCtD
Naltrexone—Syncope—Prednisone—atopic dermatitis	0.000154	0.000332	CcSEcCtD
Naltrexone—Anorexia—Dexamethasone—atopic dermatitis	0.000153	0.000331	CcSEcCtD
Naltrexone—Anorexia—Betamethasone—atopic dermatitis	0.000153	0.000331	CcSEcCtD
Naltrexone—Urticaria—Prednisolone—atopic dermatitis	0.000153	0.00033	CcSEcCtD
Naltrexone—Fatigue—Triamcinolone—atopic dermatitis	0.000153	0.00033	CcSEcCtD
Naltrexone—Fatigue—Methylprednisolone—atopic dermatitis	0.000152	0.000329	CcSEcCtD
Naltrexone—Pain—Triamcinolone—atopic dermatitis	0.000151	0.000327	CcSEcCtD
Naltrexone—OPRM1—Peptide ligand-binding receptors—CXCL8—atopic dermatitis	0.000151	0.00155	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—CCR5—atopic dermatitis	0.000151	0.00155	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—CXCL8—atopic dermatitis	0.000151	0.00155	CbGpPWpGaD
Naltrexone—Loss of consciousness—Prednisone—atopic dermatitis	0.000151	0.000325	CcSEcCtD
Naltrexone—Urticaria—Hydrocortisone—atopic dermatitis	0.000149	0.000323	CcSEcCtD
Naltrexone—Body temperature increased—Hydrocortisone—atopic dermatitis	0.000149	0.000321	CcSEcCtD
Naltrexone—Abdominal pain—Hydrocortisone—atopic dermatitis	0.000149	0.000321	CcSEcCtD
Naltrexone—Convulsion—Prednisone—atopic dermatitis	0.000148	0.000321	CcSEcCtD
Naltrexone—Hypertension—Prednisone—atopic dermatitis	0.000148	0.00032	CcSEcCtD
Naltrexone—OPRD1—GPCR downstream signaling—IL5—atopic dermatitis	0.000147	0.00151	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CCL11—atopic dermatitis	0.000147	0.00151	CbGpPWpGaD
Naltrexone—Musculoskeletal discomfort—Dexamethasone—atopic dermatitis	0.000146	0.000316	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Betamethasone—atopic dermatitis	0.000146	0.000316	CcSEcCtD
Naltrexone—Myalgia—Prednisone—atopic dermatitis	0.000146	0.000315	CcSEcCtD
Naltrexone—Arthralgia—Prednisone—atopic dermatitis	0.000146	0.000315	CcSEcCtD
Naltrexone—Feeling abnormal—Triamcinolone—atopic dermatitis	0.000146	0.000315	CcSEcCtD
Naltrexone—Feeling abnormal—Methylprednisolone—atopic dermatitis	0.000145	0.000314	CcSEcCtD
Naltrexone—Anxiety—Prednisone—atopic dermatitis	0.000145	0.000314	CcSEcCtD
Naltrexone—Insomnia—Dexamethasone—atopic dermatitis	0.000145	0.000314	CcSEcCtD
Naltrexone—Insomnia—Betamethasone—atopic dermatitis	0.000145	0.000314	CcSEcCtD
Naltrexone—OPRD1—Signaling Pathways—CCL17—atopic dermatitis	0.000145	0.00149	CbGpPWpGaD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—atopic dermatitis	0.000145	0.000313	CcSEcCtD
Naltrexone—OPRM1—Signaling Pathways—FCER2—atopic dermatitis	0.000145	0.00149	CbGpPWpGaD
Naltrexone—Gastrointestinal pain—Methylprednisolone—atopic dermatitis	0.000144	0.000312	CcSEcCtD
Naltrexone—Paraesthesia—Dexamethasone—atopic dermatitis	0.000144	0.000312	CcSEcCtD
Naltrexone—Paraesthesia—Betamethasone—atopic dermatitis	0.000144	0.000312	CcSEcCtD
Naltrexone—Discomfort—Prednisone—atopic dermatitis	0.000144	0.000311	CcSEcCtD
Naltrexone—OPRD1—Signaling by GPCR—NPS—atopic dermatitis	0.000144	0.00148	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—TAC1—atopic dermatitis	0.000144	0.00148	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—CXCL8—atopic dermatitis	0.000143	0.00147	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCL27—atopic dermatitis	0.000142	0.00146	CbGpPWpGaD
Naltrexone—Hypersensitivity—Prednisolone—atopic dermatitis	0.000142	0.000306	CcSEcCtD
Naltrexone—OPRM1—GPCR ligand binding—CCL5—atopic dermatitis	0.000142	0.00146	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CCR3—atopic dermatitis	0.000141	0.00145	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CXCR3—atopic dermatitis	0.000141	0.00145	CbGpPWpGaD
Naltrexone—Urticaria—Triamcinolone—atopic dermatitis	0.000141	0.000304	CcSEcCtD
Naltrexone—Urticaria—Methylprednisolone—atopic dermatitis	0.00014	0.000303	CcSEcCtD
Naltrexone—Body temperature increased—Triamcinolone—atopic dermatitis	0.00014	0.000302	CcSEcCtD
Naltrexone—UGT1A1—Metabolism—GLB1—atopic dermatitis	0.00014	0.00144	CbGpPWpGaD
Naltrexone—Oedema—Prednisone—atopic dermatitis	0.00014	0.000302	CcSEcCtD
Naltrexone—Anaphylactic shock—Prednisone—atopic dermatitis	0.00014	0.000302	CcSEcCtD
Naltrexone—Abdominal pain—Methylprednisolone—atopic dermatitis	0.00014	0.000302	CcSEcCtD
Naltrexone—Decreased appetite—Betamethasone—atopic dermatitis	0.00014	0.000302	CcSEcCtD
Naltrexone—Decreased appetite—Dexamethasone—atopic dermatitis	0.00014	0.000302	CcSEcCtD
Naltrexone—Infection—Prednisone—atopic dermatitis	0.000139	0.0003	CcSEcCtD
Naltrexone—OPRK1—GPCR downstream signaling—TAC1—atopic dermatitis	0.000139	0.00143	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—NPS—atopic dermatitis	0.000139	0.00143	CbGpPWpGaD
Naltrexone—Gastrointestinal disorder—Betamethasone—atopic dermatitis	0.000139	0.0003	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Dexamethasone—atopic dermatitis	0.000139	0.0003	CcSEcCtD
Naltrexone—Hypersensitivity—Hydrocortisone—atopic dermatitis	0.000138	0.000299	CcSEcCtD
Naltrexone—Fatigue—Betamethasone—atopic dermatitis	0.000138	0.000299	CcSEcCtD
Naltrexone—Fatigue—Dexamethasone—atopic dermatitis	0.000138	0.000299	CcSEcCtD
Naltrexone—Shock—Prednisone—atopic dermatitis	0.000138	0.000297	CcSEcCtD
Naltrexone—Pain—Betamethasone—atopic dermatitis	0.000137	0.000297	CcSEcCtD
Naltrexone—Pain—Dexamethasone—atopic dermatitis	0.000137	0.000297	CcSEcCtD
Naltrexone—ABCB1—Allograft Rejection—IL1B—atopic dermatitis	0.000137	0.00141	CbGpPWpGaD
Naltrexone—Nervous system disorder—Prednisone—atopic dermatitis	0.000137	0.000296	CcSEcCtD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL8—atopic dermatitis	0.000137	0.0014	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—IL2—atopic dermatitis	0.000137	0.0014	CbGpPWpGaD
Naltrexone—Tachycardia—Prednisone—atopic dermatitis	0.000136	0.000295	CcSEcCtD
Naltrexone—OPRK1—GPCR downstream signaling—CXCR3—atopic dermatitis	0.000136	0.0014	CbGpPWpGaD
Naltrexone—Skin disorder—Prednisone—atopic dermatitis	0.000136	0.000294	CcSEcCtD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—atopic dermatitis	0.000135	0.00139	CbGpPWpGaD
Naltrexone—Hyperhidrosis—Prednisone—atopic dermatitis	0.000135	0.000292	CcSEcCtD
Naltrexone—Asthenia—Hydrocortisone—atopic dermatitis	0.000135	0.000291	CcSEcCtD
Naltrexone—OPRM1—Signaling Pathways—CCL22—atopic dermatitis	0.000134	0.00138	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ADSL—atopic dermatitis	0.000134	0.00138	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL5—atopic dermatitis	0.000134	0.00137	CbGpPWpGaD
Naltrexone—Anorexia—Prednisone—atopic dermatitis	0.000133	0.000288	CcSEcCtD
Naltrexone—Pruritus—Hydrocortisone—atopic dermatitis	0.000133	0.000287	CcSEcCtD
Naltrexone—Feeling abnormal—Dexamethasone—atopic dermatitis	0.000132	0.000286	CcSEcCtD
Naltrexone—Feeling abnormal—Betamethasone—atopic dermatitis	0.000132	0.000286	CcSEcCtD
Naltrexone—OPRM1—GPCR downstream signaling—CCR3—atopic dermatitis	0.000132	0.00135	CbGpPWpGaD
Naltrexone—Gastrointestinal pain—Dexamethasone—atopic dermatitis	0.000131	0.000284	CcSEcCtD
Naltrexone—Gastrointestinal pain—Betamethasone—atopic dermatitis	0.000131	0.000284	CcSEcCtD
Naltrexone—Hypersensitivity—Triamcinolone—atopic dermatitis	0.00013	0.000282	CcSEcCtD
Naltrexone—Hypersensitivity—Methylprednisolone—atopic dermatitis	0.00013	0.000281	CcSEcCtD
Naltrexone—OPRD1—Signaling Pathways—KIF3A—atopic dermatitis	0.000129	0.00133	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—IL5—atopic dermatitis	0.000129	0.00133	CbGpPWpGaD
Naltrexone—Diarrhoea—Hydrocortisone—atopic dermatitis	0.000129	0.000278	CcSEcCtD
Naltrexone—OPRM1—GPCR ligand binding—CCR5—atopic dermatitis	0.000128	0.00131	CbGpPWpGaD
Naltrexone—Urticaria—Betamethasone—atopic dermatitis	0.000128	0.000276	CcSEcCtD
Naltrexone—Urticaria—Dexamethasone—atopic dermatitis	0.000128	0.000276	CcSEcCtD
Naltrexone—OPRM1—G alpha (i) signalling events—CXCL8—atopic dermatitis	0.000127	0.00131	CbGpPWpGaD
Naltrexone—Musculoskeletal discomfort—Prednisone—atopic dermatitis	0.000127	0.000275	CcSEcCtD
Naltrexone—Dizziness—Prednisolone—atopic dermatitis	0.000127	0.000275	CcSEcCtD
Naltrexone—OPRK1—Signaling Pathways—CCL17—atopic dermatitis	0.000127	0.00131	CbGpPWpGaD
Naltrexone—Asthenia—Triamcinolone—atopic dermatitis	0.000127	0.000274	CcSEcCtD
Naltrexone—Body temperature increased—Dexamethasone—atopic dermatitis	0.000127	0.000274	CcSEcCtD
Naltrexone—Abdominal pain—Dexamethasone—atopic dermatitis	0.000127	0.000274	CcSEcCtD
Naltrexone—Abdominal pain—Betamethasone—atopic dermatitis	0.000127	0.000274	CcSEcCtD
Naltrexone—Body temperature increased—Betamethasone—atopic dermatitis	0.000127	0.000274	CcSEcCtD
Naltrexone—Asthenia—Methylprednisolone—atopic dermatitis	0.000127	0.000274	CcSEcCtD
Naltrexone—Insomnia—Prednisone—atopic dermatitis	0.000126	0.000273	CcSEcCtD
Naltrexone—OPRK1—Signaling by GPCR—NPS—atopic dermatitis	0.000126	0.00129	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—TAC1—atopic dermatitis	0.000126	0.00129	CbGpPWpGaD
Naltrexone—Paraesthesia—Prednisone—atopic dermatitis	0.000126	0.000271	CcSEcCtD
Naltrexone—OPRD1—GPCR downstream signaling—CXCL10—atopic dermatitis	0.000126	0.00129	CbGpPWpGaD
Naltrexone—Pruritus—Triamcinolone—atopic dermatitis	0.000125	0.000271	CcSEcCtD
Naltrexone—Pruritus—Methylprednisolone—atopic dermatitis	0.000125	0.00027	CcSEcCtD
Naltrexone—Dizziness—Hydrocortisone—atopic dermatitis	0.000124	0.000269	CcSEcCtD
Naltrexone—OPRK1—Signaling by GPCR—CXCR3—atopic dermatitis	0.000124	0.00127	CbGpPWpGaD
Naltrexone—Decreased appetite—Prednisone—atopic dermatitis	0.000122	0.000263	CcSEcCtD
Naltrexone—Rash—Prednisolone—atopic dermatitis	0.000121	0.000262	CcSEcCtD
Naltrexone—Dermatitis—Prednisolone—atopic dermatitis	0.000121	0.000262	CcSEcCtD
Naltrexone—Diarrhoea—Methylprednisolone—atopic dermatitis	0.000121	0.000261	CcSEcCtD
Naltrexone—Fatigue—Prednisone—atopic dermatitis	0.000121	0.000261	CcSEcCtD
Naltrexone—Headache—Prednisolone—atopic dermatitis	0.000121	0.000261	CcSEcCtD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL8—atopic dermatitis	0.00012	0.00123	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCL27—atopic dermatitis	0.00012	0.00123	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CCR3—atopic dermatitis	0.00012	0.00123	CbGpPWpGaD
Naltrexone—Constipation—Prednisone—atopic dermatitis	0.00012	0.000258	CcSEcCtD
Naltrexone—Vomiting—Hydrocortisone—atopic dermatitis	0.000119	0.000258	CcSEcCtD
Naltrexone—Rash—Hydrocortisone—atopic dermatitis	0.000118	0.000256	CcSEcCtD
Naltrexone—Dermatitis—Hydrocortisone—atopic dermatitis	0.000118	0.000256	CcSEcCtD
Naltrexone—Headache—Hydrocortisone—atopic dermatitis	0.000118	0.000254	CcSEcCtD
Naltrexone—OPRM1—GPCR downstream signaling—TAC1—atopic dermatitis	0.000117	0.00121	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—NPS—atopic dermatitis	0.000117	0.00121	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL5—atopic dermatitis	0.000117	0.0012	CbGpPWpGaD
Naltrexone—Dizziness—Triamcinolone—atopic dermatitis	0.000117	0.000253	CcSEcCtD
Naltrexone—OPRD1—Signaling Pathways—CMA1—atopic dermatitis	0.000117	0.0012	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCL11—atopic dermatitis	0.000117	0.0012	CbGpPWpGaD
Naltrexone—Dizziness—Methylprednisolone—atopic dermatitis	0.000117	0.000252	CcSEcCtD
Naltrexone—Feeling abnormal—Prednisone—atopic dermatitis	0.000115	0.000249	CcSEcCtD
Naltrexone—Asthenia—Betamethasone—atopic dermatitis	0.000115	0.000249	CcSEcCtD
Naltrexone—Asthenia—Dexamethasone—atopic dermatitis	0.000115	0.000249	CcSEcCtD
Naltrexone—OPRM1—GPCR downstream signaling—CXCR3—atopic dermatitis	0.000115	0.00118	CbGpPWpGaD
Naltrexone—Gastrointestinal pain—Prednisone—atopic dermatitis	0.000114	0.000247	CcSEcCtD
Naltrexone—Nausea—Prednisolone—atopic dermatitis	0.000114	0.000247	CcSEcCtD
Naltrexone—OPRD1—Signaling by GPCR—CXCL10—atopic dermatitis	0.000114	0.00117	CbGpPWpGaD
Naltrexone—Pruritus—Betamethasone—atopic dermatitis	0.000114	0.000245	CcSEcCtD
Naltrexone—Pruritus—Dexamethasone—atopic dermatitis	0.000114	0.000245	CcSEcCtD
Naltrexone—OPRK1—Signaling Pathways—KIF3A—atopic dermatitis	0.000113	0.00116	CbGpPWpGaD
Naltrexone—Vomiting—Triamcinolone—atopic dermatitis	0.000112	0.000243	CcSEcCtD
Naltrexone—Vomiting—Methylprednisolone—atopic dermatitis	0.000112	0.000243	CcSEcCtD
Naltrexone—Nausea—Hydrocortisone—atopic dermatitis	0.000112	0.000241	CcSEcCtD
Naltrexone—Rash—Triamcinolone—atopic dermatitis	0.000112	0.000241	CcSEcCtD
Naltrexone—Dermatitis—Triamcinolone—atopic dermatitis	0.000111	0.000241	CcSEcCtD
Naltrexone—Rash—Methylprednisolone—atopic dermatitis	0.000111	0.000241	CcSEcCtD
Naltrexone—Dermatitis—Methylprednisolone—atopic dermatitis	0.000111	0.00024	CcSEcCtD
Naltrexone—Urticaria—Prednisone—atopic dermatitis	0.000111	0.00024	CcSEcCtD
Naltrexone—Headache—Triamcinolone—atopic dermatitis	0.000111	0.00024	CcSEcCtD
Naltrexone—Headache—Methylprednisolone—atopic dermatitis	0.000111	0.000239	CcSEcCtD
Naltrexone—Body temperature increased—Prednisone—atopic dermatitis	0.000111	0.000239	CcSEcCtD
Naltrexone—Abdominal pain—Prednisone—atopic dermatitis	0.000111	0.000239	CcSEcCtD
Naltrexone—OPRK1—GPCR downstream signaling—CXCL10—atopic dermatitis	0.00011	0.00113	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—STAT6—atopic dermatitis	0.00011	0.00113	CbGpPWpGaD
Naltrexone—Diarrhoea—Dexamethasone—atopic dermatitis	0.00011	0.000237	CcSEcCtD
Naltrexone—Diarrhoea—Betamethasone—atopic dermatitis	0.00011	0.000237	CcSEcCtD
Naltrexone—OPRM1—GPCR downstream signaling—IL5—atopic dermatitis	0.000109	0.00112	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CCL5—atopic dermatitis	0.000108	0.00111	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCL17—atopic dermatitis	0.000108	0.0011	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—NPS—atopic dermatitis	0.000107	0.00109	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—TAC1—atopic dermatitis	0.000107	0.00109	CbGpPWpGaD
Naltrexone—Dizziness—Betamethasone—atopic dermatitis	0.000106	0.000229	CcSEcCtD
Naltrexone—Dizziness—Dexamethasone—atopic dermatitis	0.000106	0.000229	CcSEcCtD
Naltrexone—Nausea—Triamcinolone—atopic dermatitis	0.000105	0.000227	CcSEcCtD
Naltrexone—Nausea—Methylprednisolone—atopic dermatitis	0.000105	0.000227	CcSEcCtD
Naltrexone—OPRM1—Signaling by GPCR—CXCR3—atopic dermatitis	0.000105	0.00107	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—CXCL8—atopic dermatitis	0.000104	0.00107	CbGpPWpGaD
Naltrexone—Hypersensitivity—Prednisone—atopic dermatitis	0.000103	0.000223	CcSEcCtD
Naltrexone—OPRK1—Signaling Pathways—CCL11—atopic dermatitis	0.000103	0.00105	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CMA1—atopic dermatitis	0.000103	0.00105	CbGpPWpGaD
Naltrexone—Vomiting—Dexamethasone—atopic dermatitis	0.000102	0.000221	CcSEcCtD
Naltrexone—Vomiting—Betamethasone—atopic dermatitis	0.000102	0.000221	CcSEcCtD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—atopic dermatitis	0.000101	0.00104	CbGpPWpGaD
Naltrexone—Rash—Dexamethasone—atopic dermatitis	0.000101	0.000219	CcSEcCtD
Naltrexone—Rash—Betamethasone—atopic dermatitis	0.000101	0.000219	CcSEcCtD
Naltrexone—Dermatitis—Betamethasone—atopic dermatitis	0.000101	0.000219	CcSEcCtD
Naltrexone—Dermatitis—Dexamethasone—atopic dermatitis	0.000101	0.000219	CcSEcCtD
Naltrexone—Headache—Dexamethasone—atopic dermatitis	0.000101	0.000217	CcSEcCtD
Naltrexone—Headache—Betamethasone—atopic dermatitis	0.000101	0.000217	CcSEcCtD
Naltrexone—Asthenia—Prednisone—atopic dermatitis	0.0001	0.000217	CcSEcCtD
Naltrexone—OPRK1—Signaling by GPCR—CXCL10—atopic dermatitis	0.0001	0.00103	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—TNF—atopic dermatitis	9.96e-05	0.00102	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL5—atopic dermatitis	9.91e-05	0.00102	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—atopic dermatitis	9.9e-05	0.00102	CbGpPWpGaD
Naltrexone—Pruritus—Prednisone—atopic dermatitis	9.89e-05	0.000214	CcSEcCtD
Naltrexone—OPRD1—Signaling by GPCR—CCL5—atopic dermatitis	9.81e-05	0.00101	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CCR5—atopic dermatitis	9.74e-05	0.001	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—STAT6—atopic dermatitis	9.64e-05	0.00099	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KIF3A—atopic dermatitis	9.58e-05	0.000984	CbGpPWpGaD
Naltrexone—Diarrhoea—Prednisone—atopic dermatitis	9.57e-05	0.000207	CcSEcCtD
Naltrexone—Nausea—Betamethasone—atopic dermatitis	9.54e-05	0.000206	CcSEcCtD
Naltrexone—Nausea—Dexamethasone—atopic dermatitis	9.54e-05	0.000206	CcSEcCtD
Naltrexone—OPRD1—Signaling Pathways—CCR3—atopic dermatitis	9.53e-05	0.000979	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CCL5—atopic dermatitis	9.48e-05	0.000973	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CXCL10—atopic dermatitis	9.3e-05	0.000955	CbGpPWpGaD
Naltrexone—Dizziness—Prednisone—atopic dermatitis	9.25e-05	0.0002	CcSEcCtD
Naltrexone—ABCB1—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	9.18e-05	0.000942	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—CXCL8—atopic dermatitis	9.13e-05	0.000938	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—atopic dermatitis	8.93e-05	0.000917	CbGpPWpGaD
Naltrexone—Vomiting—Prednisone—atopic dermatitis	8.89e-05	0.000192	CcSEcCtD
Naltrexone—OPRD1—Signaling by GPCR—CCR5—atopic dermatitis	8.84e-05	0.000908	CbGpPWpGaD
Naltrexone—Rash—Prednisone—atopic dermatitis	8.82e-05	0.000191	CcSEcCtD
Naltrexone—Dermatitis—Prednisone—atopic dermatitis	8.81e-05	0.00019	CcSEcCtD
Naltrexone—Headache—Prednisone—atopic dermatitis	8.76e-05	0.000189	CcSEcCtD
Naltrexone—OPRM1—Signaling Pathways—CCL11—atopic dermatitis	8.67e-05	0.00089	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CMA1—atopic dermatitis	8.67e-05	0.00089	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CCL5—atopic dermatitis	8.61e-05	0.000884	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CCR5—atopic dermatitis	8.54e-05	0.000877	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NPS—atopic dermatitis	8.5e-05	0.000872	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TAC1—atopic dermatitis	8.5e-05	0.000872	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CXCL10—atopic dermatitis	8.45e-05	0.000867	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCR3—atopic dermatitis	8.36e-05	0.000858	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CXCR3—atopic dermatitis	8.33e-05	0.000855	CbGpPWpGaD
Naltrexone—Nausea—Prednisone—atopic dermatitis	8.3e-05	0.000179	CcSEcCtD
Naltrexone—OPRM1—Signaling Pathways—STAT6—atopic dermatitis	8.15e-05	0.000837	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CCL5—atopic dermatitis	8.01e-05	0.000822	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL5—atopic dermatitis	7.9e-05	0.000811	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CCR5—atopic dermatitis	7.75e-05	0.000796	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CXCL8—atopic dermatitis	7.72e-05	0.000793	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NPS—atopic dermatitis	7.45e-05	0.000765	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TAC1—atopic dermatitis	7.45e-05	0.000765	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CXCR3—atopic dermatitis	7.31e-05	0.00075	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CCL5—atopic dermatitis	7.27e-05	0.000747	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CCR5—atopic dermatitis	7.22e-05	0.000741	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCR3—atopic dermatitis	7.06e-05	0.000725	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL5—atopic dermatitis	6.93e-05	0.000711	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CXCL10—atopic dermatitis	6.73e-05	0.000691	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CCR5—atopic dermatitis	6.55e-05	0.000673	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GLB1—atopic dermatitis	6.41e-05	0.000659	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NPS—atopic dermatitis	6.3e-05	0.000646	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TAC1—atopic dermatitis	6.3e-05	0.000646	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—atopic dermatitis	6.21e-05	0.000638	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCR3—atopic dermatitis	6.17e-05	0.000634	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ADSL—atopic dermatitis	6.15e-05	0.000631	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CXCL10—atopic dermatitis	5.91e-05	0.000606	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CXCL8—atopic dermatitis	5.89e-05	0.000604	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL5—atopic dermatitis	5.85e-05	0.000601	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCL5—atopic dermatitis	5.8e-05	0.000595	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—IL2—atopic dermatitis	5.63e-05	0.000578	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NGF—atopic dermatitis	5.37e-05	0.000551	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CXCL8—atopic dermatitis	5.35e-05	0.000549	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCR5—atopic dermatitis	5.22e-05	0.000536	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CXCL8—atopic dermatitis	5.16e-05	0.00053	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL2—atopic dermatitis	5.11e-05	0.000524	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCL5—atopic dermatitis	5.08e-05	0.000522	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCL10—atopic dermatitis	4.99e-05	0.000512	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—IL2—atopic dermatitis	4.93e-05	0.000506	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—atopic dermatitis	4.91e-05	0.000505	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NGF—atopic dermatitis	4.71e-05	0.000483	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CXCL8—atopic dermatitis	4.69e-05	0.000481	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCR5—atopic dermatitis	4.58e-05	0.00047	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PPARA—atopic dermatitis	4.54e-05	0.000466	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL2—atopic dermatitis	4.48e-05	0.00046	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—PPARA—atopic dermatitis	4.44e-05	0.000456	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NFKBIA—atopic dermatitis	4.43e-05	0.000455	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CXCL8—atopic dermatitis	4.36e-05	0.000448	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCL5—atopic dermatitis	4.3e-05	0.000441	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—IL2—atopic dermatitis	4.17e-05	0.000428	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NGF—atopic dermatitis	3.98e-05	0.000409	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CXCL8—atopic dermatitis	3.96e-05	0.000407	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NFKBIA—atopic dermatitis	3.88e-05	0.000399	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCR5—atopic dermatitis	3.87e-05	0.000397	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL2—atopic dermatitis	3.79e-05	0.000389	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NFKBIA—atopic dermatitis	3.28e-05	0.000337	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CXCL8—atopic dermatitis	3.16e-05	0.000324	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL2—atopic dermatitis	3.02e-05	0.00031	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL6—atopic dermatitis	3e-05	0.000308	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MAPK8—atopic dermatitis	2.78e-05	0.000285	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CXCL8—atopic dermatitis	2.77e-05	0.000284	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL2—atopic dermatitis	2.65e-05	0.000272	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL6—atopic dermatitis	2.63e-05	0.00027	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MAPK8—atopic dermatitis	2.44e-05	0.00025	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCL8—atopic dermatitis	2.34e-05	0.00024	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL2—atopic dermatitis	2.24e-05	0.00023	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL6—atopic dermatitis	2.23e-05	0.000228	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PPARA—atopic dermatitis	2.08e-05	0.000214	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MAPK8—atopic dermatitis	2.06e-05	0.000211	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL6—atopic dermatitis	1.77e-05	0.000182	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL6—atopic dermatitis	1.56e-05	0.00016	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL6—atopic dermatitis	1.31e-05	0.000135	CbGpPWpGaD
